Regeneron Stock Hits New 52-Week High (REGN) - TheStreet



) --

Regeneron Pharmaceuticals



) hit a new 52-week high Monday as it is currently trading at $119.58, above its previous 52-week high of $119.41 with 50,811 shares traded as of 9:35 a.m. ET. Average volume has been 1.4 million shares over the past 30 days.

Regeneron has a market cap of $7.18 billion and is part of the

health care

sector and


industry. Shares are up 115% year to date as of the close of trading on Friday.

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines for the treatment of serious medical conditions in the United States.

  • Sign up for TheStreet's FREE Dividend and Income Investor Newsletter

TheStreet Ratings rates Regeneron as a


. The company's strengths can be seen in multiple areas, such as its solid stock price performance and largely solid financial position with reasonable debt levels by most measures. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, disappointing return on equity and weak operating cash flow. You can view the full

Regeneron Ratings Report


See all

52-week high stocks

or get investment ideas from our

investment research center